Overview: Flow Cytometry CD20 Panel
Introduction: The Flow Cytometry CD20 Panel is a diagnostic tool designed to assess B-cell population using whole blood samples. In India, CD20 is a key marker for mature B-cell malignancies (CLL, B-NHL) and therapeutic target (rituximab), with enumeration aiding diagnosis and monitoring. High morbidity from under-testing in rural/low-SES patients with lymphadenopathy or cytopenias, limited flow labs, delayed rituximab-based therapy leading to progression. Per hematology/immunology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs flow cytometry for CD20+ cell count, total lymphocytes, and B-cell profile over 1-2 days with high accuracy, valuable for lymphoma/CLL subtyping and therapy selection. This diagnostic falls under immune profiling and targets patients with suspected B-cell malignancy, addressing accurate detection to guide rituximab or other targeted agents. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise immunophenotyping and improving outcomes. Its whole blood-based approach ensures reliable B-cell analysis.
Other Names: Flow CD20 Pnl.
FDA Status: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.
Historical Milestone: CD20 flow standard; in India, used in lymphoma protocols.
Purpose: The test assesses 3 parameters including CD20+ cell count to guide B-cell population evaluation, detect abnormalities, inform therapy.
Test Parameters: 1. CD20+ Cell Count, 2. Total Lymphocytes, 3. B-Cell Profile.
Pretest Condition: No fasting required; patients should have suspected B-cell disorder.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow).
Medical History: Patients should provide details on lymphadenopathy, cytopenias, prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed B-cell disorder including progression, benefits of profiling, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal CD20+ population indicates B-cell disorder, necessitating specialist input. Normal may require follow-up.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: Full immunophenotyping, biopsy for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Flow Studies India 2023.
